Consistent with the previous findings that B16F10 tumors are largely refractory to PD-1/PD-L1 blockade therapy [39, 40], anti-PD-L1 antibody treatment in B16F10 tumor-bearing CD244fl/fl mice did not induce significant changes in tumor growth. This evidence concerns the gene CD274 and neoplasm.